Pfizer announced positive topline results for its investigational trispecific antibody, tilrekimig, which demonstrated significant skin clearance in adults with moderate to severe eczema and paved the way for a pivotal Phase 3 study later this year.
Pfizer (NYSE:PFE) revealed Monday that tilrekimig (PF-07275315) met its primary efficacy endpoint in a Phase 2 study, showing a statistically significant increase in the percentage of patients achieving 75% skin clearance (EASI-75) at Week 16 compared to placebo.
The drug is a potential first-in-class trispecific antibody designed to simultaneously target three key inflammatory pathways: IL-4, IL-13, and TSLP.
In the dose-ranging portion of the trial, the monthly middle and high doses showed placebo-adjusted EASI-75 rates of 51.9% and 49.4%, respectively.
Pfizer management noted that these results suggest tilrekimig could offer meaningful improvements over current standard-of-care biologics.
Unlike some existing treatments, tilrekimig’s mechanism targets multiple drivers of Type 2 immune responses without affecting receptors on healthy cells.
The safety profile remained favorable with no dose-dependent signals.
Notably, the observed frequency of conjunctivitis—a common side effect associated with some IL-4 receptor inhibitors—was lower in the tilrekimig study.
While three serious adverse events were reported, all were deemed unrelated to the treatment.
Beyond atopic dermatitis, Pfizer is aggressively expanding the tilrekimig clinical program.
The company has already initiated a Phase 2b/3 study for chronic obstructive pulmonary disease (COPD) and is conducting a Phase 2 study for asthma.
Detailed data from the eczema trial will be presented at a future medical meeting as the company prepares to launch its pivotal Phase 3 program in 2026.